Medicare expanded coverage for Personalis’ NeXT Personal minimal residual disease assay to include immunotherapy monitoring across late-stage solid tumors, following earlier coverage for recurrence monitoring in breast and non-small cell lung cancer. The decision was attributed to sensitivity evidence from a study conducted with Spain’s Vall d’Hebron Institute of Oncology. Reimbursement expansions for liquid biopsy-based MRD tests can materially change utilization patterns because they shift ordering from research frameworks to routine clinical pathways. Analysts said the immuno-oncology indication could add upside if reimbursement rates align with other covered uses. In parallel, the broader availability of genomic profiling tests like Datar’s CellDx-Tissue underscores a continued push toward multiplex, action-oriented tumor diagnostics.